Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Lingjuan Chen"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background Investigating the molecular mechanism of colorectal cancer (CRC), a common lethal malignancies worldwide, is of great clinical significance. Solute carrier family 25 member 19 (SLC25A19) is a member of the solute carrier family th
Externí odkaz:
https://doaj.org/article/af3f4b5bc6b9452db4eee55e14819688
Autor:
Lichao Liu, Jian Wang, Ying Wang, Lingjuan Chen, Ling Peng, Yawen Bin, Peng Ding, Ruiguang Zhang, Fan Tong, Xiaorong Dong
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-20 (2024)
Abstract Background Brain metastasis is one of the main causes of recurrence and death in non-small cell lung cancer (NSCLC). Although radiotherapy is the main local therapy for brain metastasis, it is inevitable that some cancer cells become resista
Externí odkaz:
https://doaj.org/article/836e2093d6fa48c1b229690be5a03dc9
Publikováno v:
Transport, Vol 39, Iss 1 (2024)
Stability analysis and benefit estimation have substantial implications for lane-change decision-making to reduce delay and variation. Connected platoons drive with minor headway to increase capacity, whereas dividing or reforming platoons significan
Externí odkaz:
https://doaj.org/article/644bffa8ac4848dd980c24820e296afa
Autor:
Ling Peng, Yawen Bin, Peng Ding, Lingjuan Chen, Hao Zeng, Zelong Xu, Liyan Ji, Xuan Gao, Pian Liu, Ye Wang, Sheng Zhang, Zhongxing Liao, Xuefeng Xia, Ruiguang Zhang, Fan Tong, Xiaorong Dong
Publikováno v:
Cancer Communications, Vol 43, Iss 5, Pp 625-629 (2023)
Externí odkaz:
https://doaj.org/article/25375e8ebf144ab78f99ce2c020c672d
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered to express transgenes, modulating the tumor microenvironment (TME), and h
Externí odkaz:
https://doaj.org/article/5cbdedc2043346ea84743972634ddc68
Autor:
Junjie Ye, Lingjuan Chen, Julia Waltermire, Jinshun Zhao, Jinghua Ren, Zongsheng Guo, David L. Bartlett, Zuqiang Liu
Publikováno v:
Cancers, Vol 16, Iss 5, p 1021 (2024)
The success of cancer immunotherapy is largely associated with immunologically hot tumors. Approaches that promote the infiltration of immune cells into tumor beds are urgently needed to transform cold tumors into hot tumors. Oncolytic viruses can tr
Externí odkaz:
https://doaj.org/article/74503ba062b0432481722c8c5d30f326
Publikováno v:
Analytical Cellular Pathology, Vol 2023 (2023)
Hypoxic conditions are a typical extrinsic factor for the modification of trophoblast biological functions, including cell proliferation, migration, and invasion. Hypoxia-induced reactive oxygen species (ROS) accumulation causes chronic trophoblast i
Externí odkaz:
https://doaj.org/article/8e0e3f13c6fd4ef9875ee935b4804824
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA for advanced HCC in first-line or seco
Externí odkaz:
https://doaj.org/article/1406ed17fbd74e9ba23e956e48eec291
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundImmune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological
Externí odkaz:
https://doaj.org/article/a707008e76634f43bc6152fbea74dc5b
Autor:
Qiwen Li, Li Ma, Bo Qiu, Yuzhi Wen, Wenhua Liang, Wanming Hu, Naibin Chen, Tian Zhang, Shuangbing Xu, Lingjuan Chen, Minzhang Guo, Yi Zhao, Songran Liu, Jinyu Guo, Junye Wang, Siyu Wang, Xin Wang, Qingsong Pang, Hao Long, Hui Liu
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1424-1436 (2021)
Background: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of ad
Externí odkaz:
https://doaj.org/article/21b7fcea66f2470d9451bdc59acd8175